Apricus Biosciences (NASDAQ:APRI) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ®. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California. “
Separately, HC Wainwright reissued a “buy” rating and set a $4.50 target price on shares of Apricus Biosciences in a research report on Friday, November 3rd.
Apricus Biosciences (NASDAQ:APRI) last released its earnings results on Thursday, November 2nd. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.15). During the same quarter in the previous year, the company earned ($0.19) earnings per share. equities analysts forecast that Apricus Biosciences will post -0.6 earnings per share for the current fiscal year.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.